Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects
The aim of this study was to identify the effects of cyclooxygenase (COX)-1 and -2 inhibition each on insulin sensitivity in healthy subjects. A randomized, double-blind, controlled clinical trial was carried out in 21 young, healthy, non-obese male volunteers. Pharmacological COX-1 inhibition was p...
Gespeichert in:
Veröffentlicht in: | Hormone and metabolic research 2001-04, Vol.33 (4), p.250-253 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 253 |
---|---|
container_issue | 4 |
container_start_page | 250 |
container_title | Hormone and metabolic research |
container_volume | 33 |
creator | González-Ortiz, M Martínez-Abundis, E Balcázar-Muñoz, B R Robles-Cervantes, J A |
description | The aim of this study was to identify the effects of cyclooxygenase (COX)-1 and -2 inhibition each on insulin sensitivity in healthy subjects. A randomized, double-blind, controlled clinical trial was carried out in 21 young, healthy, non-obese male volunteers. Pharmacological COX-1 inhibition was performed with the prescription of acetylsalicylic acid (ASA) at a low dose, and COX-2 selective inhibition was performed with celecoxib. After randomization, all subjects received an oral morning dose of ASA 100 mg (n = 7), celecoxib 200 mg (n = 7), or placebo for the control group (n = 7) during a period of 15 days. Before and after of the study period, a metabolic profile was measured in all participants. An insulin tolerance test (ITT) was performed to assess insulin sensitivity, and the constant for the serum glucose disappearance rate (K ITT) was calculated. Clinical and metabolic characteristics were similar between groups. The K ITT calculated with the ITT was higher after celecoxib than at baseline (4.8 +/- 0.9 vs. 4.3 +/- 0.6%/min, p = 0.04), indicating improvement in insulin sensitivity. Neither ASA nor placebo administrations modified insulin sensitivity. In conclusion, COX-2-selective inhibitor at a celecoxib dose of 200 mg daily increased insulin sensitivity in healthy subjects. |
doi_str_mv | 10.1055/s-2001-14949 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70878961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70878961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-50d45c1797591c4370a273657ece4ae7e0e6c9aa1dafaef6baaa180fd393a883</originalsourceid><addsrcrecordid>eNpFkL1PwzAQxS0EoqWwMSNPTBjs2onjESE-KlXq0t1ynAt1lcYllyDy3-PSSkx39-6np6dHyK3gj4Jn2ROyOeeCCWWUOSNToaRhal7k52Sa9IJlXMkJuULcplMZoS7JRAhZSCPFlKwW7SaUoQ-xpbGmfvRNjD_jJ7QOgQkaO8rmND1Di0MTWorQYsK_Qz8mjW7ANf1mpDiUW_A9XpOL2jUIN6c5I-u31_XLB1uu3hcvz0vmZSb7FKpSmRfa6MwIr6Tmbq5lnmnwoBxo4JB745yoXO2gzkuX9oLXVUrtikLOyP3Rdt_FrwGwt7uAHprGtRAHtJoXujC5SODDEfRdROygtvsu7Fw3WsHtoT-L9tCf_esv4Xcn36HcQfUPnwqTvwDEa3U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70878961</pqid></control><display><type>article</type><title>Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>González-Ortiz, M ; Martínez-Abundis, E ; Balcázar-Muñoz, B R ; Robles-Cervantes, J A</creator><creatorcontrib>González-Ortiz, M ; Martínez-Abundis, E ; Balcázar-Muñoz, B R ; Robles-Cervantes, J A</creatorcontrib><description>The aim of this study was to identify the effects of cyclooxygenase (COX)-1 and -2 inhibition each on insulin sensitivity in healthy subjects. A randomized, double-blind, controlled clinical trial was carried out in 21 young, healthy, non-obese male volunteers. Pharmacological COX-1 inhibition was performed with the prescription of acetylsalicylic acid (ASA) at a low dose, and COX-2 selective inhibition was performed with celecoxib. After randomization, all subjects received an oral morning dose of ASA 100 mg (n = 7), celecoxib 200 mg (n = 7), or placebo for the control group (n = 7) during a period of 15 days. Before and after of the study period, a metabolic profile was measured in all participants. An insulin tolerance test (ITT) was performed to assess insulin sensitivity, and the constant for the serum glucose disappearance rate (K ITT) was calculated. Clinical and metabolic characteristics were similar between groups. The K ITT calculated with the ITT was higher after celecoxib than at baseline (4.8 +/- 0.9 vs. 4.3 +/- 0.6%/min, p = 0.04), indicating improvement in insulin sensitivity. Neither ASA nor placebo administrations modified insulin sensitivity. In conclusion, COX-2-selective inhibitor at a celecoxib dose of 200 mg daily increased insulin sensitivity in healthy subjects.</description><identifier>ISSN: 0018-5043</identifier><identifier>EISSN: 1439-4286</identifier><identifier>DOI: 10.1055/s-2001-14949</identifier><identifier>PMID: 11383931</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aspirin - administration & dosage ; Celecoxib ; Cyclooxygenase 1 ; Cyclooxygenase 2 ; Cyclooxygenase 2 Inhibitors ; Cyclooxygenase Inhibitors - administration & dosage ; Double-Blind Method ; Humans ; Insulin - metabolism ; Insulin Resistance ; Isoenzymes - antagonists & inhibitors ; Male ; Membrane Proteins ; Prostaglandin-Endoperoxide Synthases ; Pyrazoles ; Reference Values ; Sulfonamides - administration & dosage</subject><ispartof>Hormone and metabolic research, 2001-04, Vol.33 (4), p.250-253</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-50d45c1797591c4370a273657ece4ae7e0e6c9aa1dafaef6baaa180fd393a883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3017,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11383931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>González-Ortiz, M</creatorcontrib><creatorcontrib>Martínez-Abundis, E</creatorcontrib><creatorcontrib>Balcázar-Muñoz, B R</creatorcontrib><creatorcontrib>Robles-Cervantes, J A</creatorcontrib><title>Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects</title><title>Hormone and metabolic research</title><addtitle>Horm Metab Res</addtitle><description>The aim of this study was to identify the effects of cyclooxygenase (COX)-1 and -2 inhibition each on insulin sensitivity in healthy subjects. A randomized, double-blind, controlled clinical trial was carried out in 21 young, healthy, non-obese male volunteers. Pharmacological COX-1 inhibition was performed with the prescription of acetylsalicylic acid (ASA) at a low dose, and COX-2 selective inhibition was performed with celecoxib. After randomization, all subjects received an oral morning dose of ASA 100 mg (n = 7), celecoxib 200 mg (n = 7), or placebo for the control group (n = 7) during a period of 15 days. Before and after of the study period, a metabolic profile was measured in all participants. An insulin tolerance test (ITT) was performed to assess insulin sensitivity, and the constant for the serum glucose disappearance rate (K ITT) was calculated. Clinical and metabolic characteristics were similar between groups. The K ITT calculated with the ITT was higher after celecoxib than at baseline (4.8 +/- 0.9 vs. 4.3 +/- 0.6%/min, p = 0.04), indicating improvement in insulin sensitivity. Neither ASA nor placebo administrations modified insulin sensitivity. In conclusion, COX-2-selective inhibitor at a celecoxib dose of 200 mg daily increased insulin sensitivity in healthy subjects.</description><subject>Adult</subject><subject>Aspirin - administration & dosage</subject><subject>Celecoxib</subject><subject>Cyclooxygenase 1</subject><subject>Cyclooxygenase 2</subject><subject>Cyclooxygenase 2 Inhibitors</subject><subject>Cyclooxygenase Inhibitors - administration & dosage</subject><subject>Double-Blind Method</subject><subject>Humans</subject><subject>Insulin - metabolism</subject><subject>Insulin Resistance</subject><subject>Isoenzymes - antagonists & inhibitors</subject><subject>Male</subject><subject>Membrane Proteins</subject><subject>Prostaglandin-Endoperoxide Synthases</subject><subject>Pyrazoles</subject><subject>Reference Values</subject><subject>Sulfonamides - administration & dosage</subject><issn>0018-5043</issn><issn>1439-4286</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkL1PwzAQxS0EoqWwMSNPTBjs2onjESE-KlXq0t1ynAt1lcYllyDy3-PSSkx39-6np6dHyK3gj4Jn2ROyOeeCCWWUOSNToaRhal7k52Sa9IJlXMkJuULcplMZoS7JRAhZSCPFlKwW7SaUoQ-xpbGmfvRNjD_jJ7QOgQkaO8rmND1Di0MTWorQYsK_Qz8mjW7ANf1mpDiUW_A9XpOL2jUIN6c5I-u31_XLB1uu3hcvz0vmZSb7FKpSmRfa6MwIr6Tmbq5lnmnwoBxo4JB745yoXO2gzkuX9oLXVUrtikLOyP3Rdt_FrwGwt7uAHprGtRAHtJoXujC5SODDEfRdROygtvsu7Fw3WsHtoT-L9tCf_esv4Xcn36HcQfUPnwqTvwDEa3U</recordid><startdate>20010401</startdate><enddate>20010401</enddate><creator>González-Ortiz, M</creator><creator>Martínez-Abundis, E</creator><creator>Balcázar-Muñoz, B R</creator><creator>Robles-Cervantes, J A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010401</creationdate><title>Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects</title><author>González-Ortiz, M ; Martínez-Abundis, E ; Balcázar-Muñoz, B R ; Robles-Cervantes, J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-50d45c1797591c4370a273657ece4ae7e0e6c9aa1dafaef6baaa180fd393a883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aspirin - administration & dosage</topic><topic>Celecoxib</topic><topic>Cyclooxygenase 1</topic><topic>Cyclooxygenase 2</topic><topic>Cyclooxygenase 2 Inhibitors</topic><topic>Cyclooxygenase Inhibitors - administration & dosage</topic><topic>Double-Blind Method</topic><topic>Humans</topic><topic>Insulin - metabolism</topic><topic>Insulin Resistance</topic><topic>Isoenzymes - antagonists & inhibitors</topic><topic>Male</topic><topic>Membrane Proteins</topic><topic>Prostaglandin-Endoperoxide Synthases</topic><topic>Pyrazoles</topic><topic>Reference Values</topic><topic>Sulfonamides - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>González-Ortiz, M</creatorcontrib><creatorcontrib>Martínez-Abundis, E</creatorcontrib><creatorcontrib>Balcázar-Muñoz, B R</creatorcontrib><creatorcontrib>Robles-Cervantes, J A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hormone and metabolic research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>González-Ortiz, M</au><au>Martínez-Abundis, E</au><au>Balcázar-Muñoz, B R</au><au>Robles-Cervantes, J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects</atitle><jtitle>Hormone and metabolic research</jtitle><addtitle>Horm Metab Res</addtitle><date>2001-04-01</date><risdate>2001</risdate><volume>33</volume><issue>4</issue><spage>250</spage><epage>253</epage><pages>250-253</pages><issn>0018-5043</issn><eissn>1439-4286</eissn><abstract>The aim of this study was to identify the effects of cyclooxygenase (COX)-1 and -2 inhibition each on insulin sensitivity in healthy subjects. A randomized, double-blind, controlled clinical trial was carried out in 21 young, healthy, non-obese male volunteers. Pharmacological COX-1 inhibition was performed with the prescription of acetylsalicylic acid (ASA) at a low dose, and COX-2 selective inhibition was performed with celecoxib. After randomization, all subjects received an oral morning dose of ASA 100 mg (n = 7), celecoxib 200 mg (n = 7), or placebo for the control group (n = 7) during a period of 15 days. Before and after of the study period, a metabolic profile was measured in all participants. An insulin tolerance test (ITT) was performed to assess insulin sensitivity, and the constant for the serum glucose disappearance rate (K ITT) was calculated. Clinical and metabolic characteristics were similar between groups. The K ITT calculated with the ITT was higher after celecoxib than at baseline (4.8 +/- 0.9 vs. 4.3 +/- 0.6%/min, p = 0.04), indicating improvement in insulin sensitivity. Neither ASA nor placebo administrations modified insulin sensitivity. In conclusion, COX-2-selective inhibitor at a celecoxib dose of 200 mg daily increased insulin sensitivity in healthy subjects.</abstract><cop>Germany</cop><pmid>11383931</pmid><doi>10.1055/s-2001-14949</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0018-5043 |
ispartof | Hormone and metabolic research, 2001-04, Vol.33 (4), p.250-253 |
issn | 0018-5043 1439-4286 |
language | eng |
recordid | cdi_proquest_miscellaneous_70878961 |
source | MEDLINE; Thieme Connect Journals |
subjects | Adult Aspirin - administration & dosage Celecoxib Cyclooxygenase 1 Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors - administration & dosage Double-Blind Method Humans Insulin - metabolism Insulin Resistance Isoenzymes - antagonists & inhibitors Male Membrane Proteins Prostaglandin-Endoperoxide Synthases Pyrazoles Reference Values Sulfonamides - administration & dosage |
title | Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A12%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20cyclooxygenase-1%20or%20-2%20on%20insulin%20sensitivity%20in%20healthy%20subjects&rft.jtitle=Hormone%20and%20metabolic%20research&rft.au=Gonz%C3%A1lez-Ortiz,%20M&rft.date=2001-04-01&rft.volume=33&rft.issue=4&rft.spage=250&rft.epage=253&rft.pages=250-253&rft.issn=0018-5043&rft.eissn=1439-4286&rft_id=info:doi/10.1055/s-2001-14949&rft_dat=%3Cproquest_cross%3E70878961%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70878961&rft_id=info:pmid/11383931&rfr_iscdi=true |